# The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

> **NCT00097344** · PHASE3 · TERMINATED · sponsor: **Intarcia Therapeutics** · enrollment: 842 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasms, Hormone-Dependent

## Interventions

- **DRUG:** Atamestane
- **DRUG:** Toremifene
- **DRUG:** Letrozole
- **DRUG:** Aromatase inhibition
- **DRUG:** Estrogen receptor blocker
- **PROCEDURE:** Hormone therapy
- **PROCEDURE:** Endocrine therapy
- **PROCEDURE:** Antiestrogen therapy

## Key facts

- **NCT ID:** NCT00097344
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 842 (—)
- **Why stopped:** Identical study Biomed 777-CLP-029 did not meet superiority endpoint
- **Last updated:** 2007-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097344, "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00097344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*